NasdaqGM:NTLABiotechs
Intellia Therapeutics (NTLA) Stock May Be Fully Priced Despite Its 92% Slide
Intellia Therapeutics stock has rebounded over the past year, yet its longer term track record and current valuation checks point to a much less flattering picture. The current market pricing appears rich compared with the broader fundamentals scorecard and the long run return profile.
Over the past 5 years, Intellia Therapeutics shareholders have seen the stock fall about 92%, which puts a spotlight on how much long term value the market believes is still on the table.
Future progress on...